Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDI-UC
2023-509775-16-00Phase 2Authorised
- Sponsor
- Children's Memorial Health Institute
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Vedolizumab (Entyvio) with Infliximab standard therapy (2 arms). Primary endpoint: Safety of biological treatment with vedolizumab and infliximab. Planned start May 2024; status: authorised.
02
Drugs
vedolizumabinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509775-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509775-16-00.